Surgery Partners, Inc.

As of June 30, 2026, Surgery Partners, Inc. carries a market capitalization of 2.20B, placing it among publicly traded companies globally. Its enterprise value stands at 7.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Surgery Partners, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Surgery Partners, Inc. has 130.89M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.64, and the price-to-book ratio stands at 1.32.

As of June 30, 2026, Surgery Partners, Inc. trades at an EV/EBITDA multiple of 13.97 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Surgery Partners, Inc. trades at an EV/FCF ratio of 18.99, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.84B versus a market cap of 2.20B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Surgery Partners, Inc. maintains a current ratio of 1.95, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 117.00, indicating elevated leverage, while an interest coverage ratio of 1.99 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Surgery Partners, Inc. posted a negative return on equity (ROE) of -5.18, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 4.10 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -1.11, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -0.45, pointing to unprofitable operations over the period. The company generates approximately 213,733.33 in revenue per employee across its workforce of 15,750.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 28.03 indicates how many times Surgery Partners, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Surgery Partners, Inc. recorded 20.50M in income tax expense. That works out to an effective tax rate of 20.02, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 102.40M, leaving -88.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 27, 2026, Surgery Partners, Inc.'s stock has gained approximately 2.01% over the past 52 weeks. The 50-day moving average sits at 14.57, while the 200-day moving average is 14.52.

Over the twelve months ended June 30, 2026, Surgery Partners, Inc. generated 3.37B in revenue and converted that into -88.60M in net income, yielding earnings per share of 0.64. EBITDA reached 561.00M, while operating income came in at 460.50M.

As of June 30, 2026, Surgery Partners, Inc. holds 216.70M in cash and equivalents against 4.06B in total debt, resulting in a net debt position of 3.53B. Total book value stands at 1.67B, with working capital of 547.50M providing operational flexibility.

Surgery Partners, Inc. produced 258.00M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -70.40M in capital expenditures, free cash flow totaled 187.60M - equivalent to 1.46 per share.

Over the twelve months ended June 30, 2026, Surgery Partners, Inc. posted a gross margin of 22.51, reflecting its pricing power and cost economics. The operating margin of 13.68 and net profit margin of -2.63 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.72, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.91, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Surgery Partners, Inc. shareholders.

As of June 30, 2026, Surgery Partners, Inc. has an Altman Z-Score of 1.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.